Literature DB >> 25150259

High expression of transcription factor 4 (TCF4) is an independent adverse prognostic factor in acute myeloid leukemia that could guide treatment decisions.

Florentien E M in 't Hout1, Bert A van der Reijden2, Davide Monteferrario1, Joop H Jansen2, Gerwin Huls3.   

Abstract

Entities:  

Keywords:  AML; TCF4; treatment

Mesh：

Substances：

Year:  2014        PMID： 25150259      PMCID： PMC4258745          DOI： 10.3324/haematol.2014.110437

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms.

Authors:  M E Massari; C Murre
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Two distinct transcription factors that bind the immunoglobulin enhancer microE5/kappa 2 motif.

Authors:  P Henthorn; M Kiledjian; T Kadesch
Journal:  Science       Date:  1990-01-26       Impact factor: 47.728

3.  Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers.

Authors:  B Corneliussen; A Thornell; B Hallberg; T Grundström
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer.

Authors:  T Ellenberger; D Fass; M Arnaud; S C Harrison
Journal:  Genes Dev       Date:  1994-04-15       Impact factor: 11.361

5.  Class A helix-loop-helix proteins are positive regulators of several cyclin-dependent kinase inhibitors' promoter activity and negatively affect cell growth.

Authors:  A Pagliuca; P Gallo; P De Luca; L Lania
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

8.  ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.

Authors:  Frank T Kolligs; Marvin T Nieman; Ira Winer; Gang Hu; David Van Mater; Ying Feng; Ian M Smith; Rong Wu; Yali Zhai; Kathleen R Cho; Eric R Fearon
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

9.  A splice variant of E2-2 basic helix-loop-helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an imperfect E-box.

Authors:  Y Liu; S K Ray; X Q Yang; V Luntz-Leybman; I M Chiu
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

10.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113
View more
  11 in total

1.  Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.

Authors:  Florentien E M In 't Hout; Mylène Gerritsen; Lars Bullinger; Bert A van der Reijden; Gerwin Huls; Edo Vellenga; Joop H Jansen
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

2.  RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Authors:  Mylène Gerritsen; Guoqiang Yi; Esther Tijchon; Jorren Kuster; Jan Jacob Schuringa; Joost H A Martens; Edo Vellenga
Journal:  Blood Adv       Date:  2019-02-12

3.  Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.

Authors:  Lin Fu; Jinlong Shi; Kai Hu; Jijun Wang; Weidong Wang; Xiaoyan Ke
Journal:  Oncotarget       Date:  2015-04-10

4.  High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.

Authors:  Jin-long Shi; Lin Fu; Wei-dong Wang
Journal:  Oncotarget       Date:  2015-03-10

5.  High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.

Authors:  Lin Fu; Huaping Fu; Lei Tian; Keman Xu; Kai Hu; Jing Wang; Jijun Wang; Hongmei Jing; Jinlong Shi; Xiaoyan Ke
Journal:  Oncotarget       Date:  2016-03-29

6.  High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.

Authors:  Jinlong Shi; Huaping Fu; Zhilong Jia; Kunlun He; Lin Fu; Weidong Wang
Journal:  EBioMedicine       Date:  2016-11-22       Impact factor: 8.143

7.  Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.

Authors:  Junwei Tang; Yu Xie; Xiaoliang Xu; Yin Yin; Runqiu Jiang; Lei Deng; Zhongming Tan; Venkatanarayana Gangarapu; Jinhai Tang; Beicheng Sun
Journal:  Cell Death Dis       Date:  2017-03-16       Impact factor: 8.469

8.  Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.

Authors:  Na Liu; Junhong Song; Yangyang Xie; Xiao-Lin Wang; Bowen Rong; Na Man; Meng-Meng Zhang; Qunling Zhang; Fei-Fei Gao; Mei-Rong Du; Ying Zhang; Jian Shen; Chun-Hui Xu; Cheng-Long Hu; Ji-Chuan Wu; Ping Liu; Yuan-Liang Zhang; Yin-Yin Xie; Ping Liu; Jin-Yan Huang; Qiu-Hua Huang; Fei Lan; Shuhong Shen; Stephen D Nimer; Zhu Chen; Sai-Juan Chen; Robert G Roeder; Lan Wang; Xiao-Jian Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-28       Impact factor: 11.205

9.  Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.

Authors:  Jin-long Shi; Lin Fu; Qing Ang; Guo-jing Wang; Jun Zhu; Wei-dong Wang
Journal:  Oncotarget       Date:  2016-01-19

10.  High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.

Authors:  Lin Fu; Huaping Fu; Qingyun Wu; Yifan Pang; Keman Xu; Lei Zhou; Jianlin Qiao; Xiaoyan Ke; Kailin Xu; Jinlong Shi
Journal:  J Transl Med       Date:  2017-07-19       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.